Press Releases

Florida Mobile Research Unit Launched with Axiom Brain Health at New Mt. Zion Baptist Church     Tampa, FL Aug 6, 2025— Brain health is being taken on the road in Tampa as Axiom Brain Health launched a new Florida-based mobile research unit that will tour the state, to improve accessibility to brain health education and […]

Data from Most Deeply Characterized Cohort Across Alzheimer’s Disease Released byGlobal Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative Washington D.C., July 31, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) and the Alzheimer’s Disease Data Initiative (AD Data Initiative) announced today that data generated from the Bio-Hermes-001 study are now publicly available. This release […]

Washington, DC -July 28, 2025 –The Global Alzheimer’s Platform Foundation® (GAP), an international leader in accelerating clinical trials and improving recruitment, announced a collaboration with Genentech, a member of the Roche Group, to expand access to clinical trials for communities underrepresented in Alzheimer’s research. This partnership will leverage the combined expertise of GAP’s Site Alliance […]

Showcase on Bio-Hermes Data Challenge and Poster Presentation to Take Place at the Alzheimer’s Association International Conference (AAIC) Washington D.C., July 23, 2025- The Global Alzheimer’s Platform Foundation® , (GAP) will have a poster presentation and a Featured Research Session at the 2025 Alzheimer’s Association International Conference (AAIC) being held in Toronto, Canada. Poster Presentation […]

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias  Washington D.C., July 22, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome IXICO, a global leader in neuroscience imaging and biomarker analytics, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study […]

For immediate release:   Contact: media@globalalzplatform.org Washington D.C., May 20, The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA’s clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer’s—a critical […]

International non-profit expands research network to Hawaii to improve access to research opportunities Washington D.C., May. 13, 2025- Global Alzheimer’s Platform Foundation ® (GAP) announces the addition of Hawaii Pacific Neuroscience a leading private clinical research organization based in Honolulu, Hawaii, to its global network of over 100 best-in-class research sites. Hawaii Pacific Neuroscience addresses the […]

GAP regrets to report that Dr. Neil Buckholtz, a valued member of the GAP Board of Directors, passed away earlier this week. Neil was a research pioneer that made singular contributions to improving the infrastructure and science pursuing therapies and cures for Alzheimer’s and related dementias.  Neil pursued several medical and health disciplines, receiving his […]

Global Researchers Recognized for Trailblazing Projects in First-of-Its-Kind Data Competition Washington D.C., Mar. 27, 2025 – International non-profit organization The Global Alzheimer’s Platform Foundation® (GAP) in collaboration with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC) and the Alzheimer’s Disease Data Initiative proudly announced four winners of the Bio-Hermes Biomarker Data Challenge  at the first Data […]

The Global Alzheimer’s Platform Foundation® (GAP) – which is focused on global game-changing dementia research working with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC)  proudly announces the first-of-its-kind Data Challenge Summit which will unveil the results stemming from the Bio-Hermes-001 Biomarker Data Challenge. The research competition was launched in February of 2024 to allow researchers early access […]

 International non-profit expands research network to Syracuse to improvecommunity access to research opportunities Washington D.C., Mar. 10, 2025- Global Alzheimer’s Platform Foundation® (GAP) announces the addition of Ichor Research, a leading private a clinical research organization based in Syracuse, New York, to its global network of over 100 best-in-class research sites. Specializing in neurodegenerative clinical trials, […]

Washington D.C., Feb. 28, 2025 -The Global Alzheimer’s Platform Foundation® (GAP) proudly announced the 2024 National Citizen Scientist Awards® elevated honorees at their 2025 GAP-Net Site Optimization Conference in Miami, Florida. GAP’s Citizen Scientist Awards (CSA) celebrate the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases. This year’s […]

Washington D.C., Feb. 18, 2025- The Global Alzheimer’s Platform Foundation ® (GAP) is gravely concerned over news of terminations of key leaders at the National Institute of Health and the Federal Drug Administration along with the firing of thousands of employees from the Department of Health and Human Services over the weekend. John Dwyer, the […]

Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data  Washington D.C., Jan. 30, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum […]

Washington D.C., Jan. 27, 2025– Global Alzheimer’s Platform Foundation® (GAP) applauds the U.S. Food and Drug Administration (FDA)’s approval of IV maintenance dosing for the treatment LEQEMBI®. With this approval, after a patient completes 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of once every four weeks […]

Tampa, Fla. Jan. 24, 2025—Axiom Brain Health (Axiom) and the Global Alzheimer’s Platform Foundation® (GAP) celebrated the next chapter in neurodegenerative research at the launch of the newly renovated site on Thursday, January 23. The expansion of the research facility accommodates the growing need for more research of Alzheimer’s, Multiple Sclerosis, Parkinson’s, and other life-threatening […]

Washington D.C., Jan. 23, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images […]

Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]

Washington D.C., Nov. 26, 2024- The Centers for Medicare & Medicaid Services (CMS) released the Clinical Laboratory Fee Schedule (CLFS) 2025 Final Rate Determinations yesterday, unveiling that clinically critical codes for the reimbursement of Alzheimer neurological biomarker blood tests have been referred to the process known as “gapfill.” Earlier this year, the preliminary recommendation for […]

Washington D.C., Nov. 18, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming a new clinical research site into its international network of best-in-class research sites, Jacksonville Center for Clinical Research of Jacksonville, Florida. Jacksonville Center for Clinical Research (JCCR) is a premier clinical research site, having conducted more than 1,000 clinical trials over 25 years with […]

Washington D.C., Nov. 4, 2024 – Global Alzheimer’s Platform Foundation® (GAP) applauds Eisai and Biogen on the completion of the rolling submission of the application to the U.S. Food and Drug Administration (FDA) for the subcutaneous maintenance dosing of Leqembi. If approved, this autoinjector could greatly improve the patient experience, reducing the need for biweekly one-hour visits […]

Global Alzheimer’s Platform Foundation Announces Strategic Partnerships for the Transformative Bio-Hermes-002 Study   Washington D.C., Oct. 28, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These collaborations will enhance the unique, observational platform study that compares blood-based and digital biomarkers across a broad range […]

October 10, 2024 The state of Florida just stood up to the assault of Hurricane Helene, followed by Milton, a ferocious one-two punch in the 2024 hurricane season.  The Global Alzheimer’s Platform Foundation® (GAP) is relieved and very grateful that our Florida GAP-Net sites, our Florida GAP partners and our own FL-based GAP team members, […]